UA103221C2 - Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини - Google Patents

Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини

Info

Publication number
UA103221C2
UA103221C2 UAA201109963A UAA201109963A UA103221C2 UA 103221 C2 UA103221 C2 UA 103221C2 UA A201109963 A UAA201109963 A UA A201109963A UA A201109963 A UAA201109963 A UA A201109963A UA 103221 C2 UA103221 C2 UA 103221C2
Authority
UA
Ukraine
Prior art keywords
stimulating factor
colony stimulating
granulocyte colony
stable formulation
recombinant human
Prior art date
Application number
UAA201109963A
Other languages
English (en)
Russian (ru)
Inventor
Джейсон Бенджамін Бок
Ксіа Луо
Original Assignee
Тева Фармасьютікал Індастріз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютікал Індастріз Лтд. filed Critical Тева Фармасьютікал Індастріз Лтд.
Publication of UA103221C2 publication Critical patent/UA103221C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується фармацевтичної композиції, що містить рекомбінантний альбумін людини-гранулоцитарний колонієстимулюючий фактор людини і щонайменше один фармацевтично прийнятний носій, де композиція має рН від 4 до 6,4, а концентрація рекомбінантного гібридного білка становить від 30 до 120 мг/мл.
UAA201109963A 2009-01-16 2010-01-15 Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини UA103221C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14543609P 2009-01-16 2009-01-16
US14544009P 2009-01-16 2009-01-16
PCT/US2010/021235 WO2010083434A2 (en) 2009-01-16 2010-01-15 New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor

Publications (1)

Publication Number Publication Date
UA103221C2 true UA103221C2 (uk) 2013-09-25

Family

ID=42260335

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201109961A UA105201C2 (uk) 2009-01-16 2010-01-15 Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопенії
UAA201109963A UA103221C2 (uk) 2009-01-16 2010-01-15 Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201109961A UA105201C2 (uk) 2009-01-16 2010-01-15 Застосування рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини для запобігання нейтропенії або лейкопенії

Country Status (16)

Country Link
US (4) US8323634B2 (uk)
EP (2) EP2387420A2 (uk)
JP (2) JP5753095B2 (uk)
KR (2) KR20110132327A (uk)
CN (2) CN102378635A (uk)
AU (2) AU2010204547B2 (uk)
BR (2) BRPI1004940A2 (uk)
CA (2) CA2749786A1 (uk)
EA (2) EA023344B1 (uk)
IL (2) IL214052A0 (uk)
MX (2) MX2011007583A (uk)
NZ (2) NZ594055A (uk)
SG (3) SG172940A1 (uk)
UA (2) UA105201C2 (uk)
WO (2) WO2010083434A2 (uk)
ZA (1) ZA201105171B (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172940A1 (en) 2009-01-16 2011-08-29 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
BR112012031121B1 (pt) * 2010-06-07 2022-09-27 Amgen Inc Dispositivo de distribuição de drogas, kit e método de operar um dispositivo de distribuição de droga utilizável
CN102628869B (zh) * 2012-04-19 2014-04-02 上海蓝怡科技有限公司 提高甲胎蛋白抗体冻干稳定性的制剂
CA2896793A1 (en) * 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Formulations of albu-bche, preparation and uses thereof
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
ES2852002T3 (es) * 2015-07-30 2021-09-10 Endor Tech S L Factor estimulante de colonias para su uso en el tratamiento del cáncer de páncreas o de colon
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
CN106222221A (zh) * 2016-08-05 2016-12-14 山东科兴生物制品有限公司 制备重组人粒细胞刺激因子原液的纯化方法
EP3544658B1 (en) 2016-11-22 2024-07-03 LTS Device Technologies Ltd Apparatus for delivering a therapeutic substance
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (ja) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
CN109420159A (zh) * 2017-08-23 2019-03-05 江苏泰康生物医药有限公司 一种重组蛋白药物的新型稳定制剂
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US20210030843A1 (en) * 2018-02-01 2021-02-04 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
EP3744368A1 (en) 2018-10-05 2020-12-02 Sorrel Medical Ltd. Triggering sequence
CN111383745A (zh) * 2018-12-29 2020-07-07 医渡云（北京）技术有限公司 计算机数据处理方法、装置、存储介质及设备
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN111751552B (zh) * 2020-06-18 2022-09-16 广州市伊川生物科技有限公司 一种缺血修饰白蛋白测定试剂盒及其使用方法
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873012B2 (ja) 1987-04-09 1999-03-24 デルタ バイオテクノロジー リミテッド 酵母ベクター
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
AU749815B2 (en) * 1998-03-06 2002-07-04 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CA2449593A1 (en) * 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1572936A2 (en) * 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2004082640A2 (en) * 2003-03-19 2004-09-30 New Century Pharmaceuticals, Inc. Human serum albumin conjugates with therapeutic compounds
US6972332B1 (en) * 2004-05-20 2005-12-06 Acura Pharmaceuticals, Inc. Process for the production of opiates
CA2618476A1 (en) 2005-08-12 2007-02-22 Human Genome Sciences, Inc. Albumin fusion proteins
CA2584927C (en) * 2006-04-13 2011-02-08 Wix Filtration Corp. A body for actuating a standpipe of a replaceable filter element
JP2008146587A (ja) * 2006-12-13 2008-06-26 Sony Corp 表示装置、表示プログラム、表示方法、画像提供装置、画像提供プログラム、画像提供方法及び記録媒体
SG172940A1 (en) 2009-01-16 2011-08-29 Teva Pharma New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein

Also Published As

Publication number Publication date
MX2011007583A (es) 2011-12-14
US8323634B2 (en) 2012-12-04
CA2749786A1 (en) 2010-07-22
EP2387420A2 (en) 2011-11-23
AU2010204552B2 (en) 2014-05-01
EA023344B1 (ru) 2016-05-31
KR20110132327A (ko) 2011-12-07
WO2010083439A2 (en) 2010-07-22
EA201190080A1 (ru) 2014-03-31
NZ594056A (en) 2013-03-28
WO2010083434A2 (en) 2010-07-22
US20130129669A1 (en) 2013-05-23
US8993519B2 (en) 2015-03-31
CN102378635A (zh) 2012-03-14
ZA201105171B (en) 2015-12-23
AU2010204547B2 (en) 2014-01-23
JP5753095B2 (ja) 2015-07-22
US20100297062A1 (en) 2010-11-25
IL214051A0 (en) 2011-08-31
CN102395379B (zh) 2015-07-22
AU2010204552A1 (en) 2011-08-04
KR20110132326A (ko) 2011-12-07
US20150202268A1 (en) 2015-07-23
IL214052A0 (en) 2011-08-31
US20100227818A1 (en) 2010-09-09
JP2012515221A (ja) 2012-07-05
EA201190079A1 (ru) 2013-02-28
EP2387419A2 (en) 2011-11-23
WO2010083439A3 (en) 2010-09-10
MX2011007582A (es) 2011-12-14
SG172941A1 (en) 2011-08-29
CN102395379A (zh) 2012-03-28
SG172940A1 (en) 2011-08-29
UA105201C2 (uk) 2014-04-25
BRPI1004940A2 (pt) 2018-06-19
JP2012515222A (ja) 2012-07-05
CA2749802C (en) 2016-08-23
CA2749802A1 (en) 2010-07-22
SG196821A1 (en) 2014-02-13
WO2010083434A3 (en) 2010-09-10
BRPI1005159A2 (pt) 2018-04-03
NZ594055A (en) 2013-03-28
AU2010204547A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
UA103221C2 (uk) Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
EP2444491A3 (en) Hyperglycosylated human coagulation factor IX
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP3626253A3 (en) Stable formulations of linaclotide
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
NZ700296A (en) Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MY164521A (en) Method of producing recombinant tat-hoxb4h protein for use as a stimulant of hematopoiesis in vivo
CU20130012A7 (es) Conjugado de factor estimulante de colonia de granulocito (g-csf)con polietileno glicol
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
GEP20156332B (en) Pyrazoles as crth2 antagonists
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
GB201101170D0 (en) Restorative materials
WO2007015918A3 (en) Novel biologically active peptides and their new uses
MX2019002894A (es) Combinaciones con un peptido ciclado con la estructura de la base.
NZ703729A (en) Combinations with a backbone-cyclized peptide
EA201200196A1 (ru) Составы для ухода за полостью рта, содержащие человеческий рекомбинантный интерлейкин-1
MX2007014803A (es) Composiciones que penetran el nucleo celular.